Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2 Study of Telaprevir (VX-950) in Combination With Peginterferon Alfa-2a (Pegasys®), and Ribavirin (Copegus®) in Subjects With Genotype 1 Hepatitis C Who Have Not Achieved Sustained Viral Response With a Prior Course of Interferon Based Therapy
Brief Summary: The PROVE3 trial is a partially double blinded, randomized, Phase 2 research study of an investigational drug, Telaprevir (VX-950) or Placebo, with Pegylated Interferon Alfa 2a (Peg-IFN-alfa-2a, Pegasys®), and Ribavirin (RBV, Copegus®) in people with genotype 1 hepatitis C who have not achieved a Sustained Viral Response (SVR) with a previous treatment of interferon therapy.


Options:
A: Arm Label: Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 24 Week; Type: EXPERIMENTAL; Interventions: Drug: Telaprevir, Drug: Ribavirin, Drug: Pegylated Interferon Alfa 2a | Arm Label: Telaprevir 24 Week+Peg-IFN-alfa-2a,RBV 48 Week; Type: EXPERIMENTAL; Interventions: Drug: Telaprevir, Drug: Ribavirin, Drug: Pegylated Interferon Alfa 2a | Arm Label: Telaprevir 24 Week+Peg-IFN-alfa-2a 24 Week; Type: EXPERIMENTAL; Interventions: Drug: Telaprevir, Drug: Pegylated Interferon Alfa 2a | Arm Label: PBO 24 Week+Peg-IFN-alfa-2a, RBV 48 Week; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ribavirin, Drug: Pegylated Interferon Alfa 2a, Drug: Matching Placebo | Intervention Type: DRUG; Name: Telaprevir; Assigned to Arm(s): Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 24 Week, Telaprevir 24 Week+Peg-IFN-alfa-2a 24 Week, Telaprevir 24 Week+Peg-IFN-alfa-2a,RBV 48 Week | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): PBO 24 Week+Peg-IFN-alfa-2a, RBV 48 Week, Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 24 Week, Telaprevir 24 Week+Peg-IFN-alfa-2a,RBV 48 Week | Intervention Type: DRUG; Name: Pegylated Interferon Alfa 2a; Assigned to Arm(s): PBO 24 Week+Peg-IFN-alfa-2a, RBV 48 Week, Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 24 Week, Telaprevir 24 Week+Peg-IFN-alfa-2a 24 Week, Telaprevir 24 Week+Peg-IFN-alfa-2a,RBV 48 Week | Intervention Type: DRUG; Name: Matching Placebo; Assigned to Arm(s): PBO 24 Week+Peg-IFN-alfa-2a, RBV 48 Week
B: Arm Label: Cohort A; Type: EXPERIMENTAL; Interventions: Drug: RO5024048 | Arm Label: Cohort B; Type: EXPERIMENTAL; Interventions: Drug: danoprevir | Arm Label: Cohort C; Type: EXPERIMENTAL; Interventions: Drug: danoprevir | Arm Label: Cohort D; Type: EXPERIMENTAL; Interventions: Drug: danoprevir | Arm Label: Cohort E; Type: EXPERIMENTAL; Interventions: Drug: danoprevir | Arm Label: Cohort F; Type: EXPERIMENTAL; Interventions: Drug: danoprevir | Arm Label: Cohort G; Type: EXPERIMENTAL; Interventions: Drug: danoprevir | Intervention Type: DRUG; Name: RO5024048; Assigned to Arm(s): Cohort A | Intervention Type: DRUG; Name: danoprevir; Assigned to Arm(s): Cohort B | Intervention Type: DRUG; Name: danoprevir; Assigned to Arm(s): Cohort C | Intervention Type: DRUG; Name: danoprevir; Assigned to Arm(s): Cohort D | Intervention Type: DRUG; Name: danoprevir; Assigned to Arm(s): Cohort E | Intervention Type: DRUG; Name: danoprevir; Assigned to Arm(s): Cohort F, Cohort G
C: Arm Label: LDV/SOF 12 weeks; Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF | Arm Label: LDV/SOF+RBV 12 weeks; Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF, Drug: RBV | Arm Label: LDV/SOF 24 weeks; Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF | Arm Label: LDV/SOF+RBV 24 weeks; Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF, Drug: RBV | Intervention Type: DRUG; Name: LDV/SOF; Assigned to Arm(s): LDV/SOF 12 weeks, LDV/SOF 24 weeks, LDV/SOF+RBV 12 weeks, LDV/SOF+RBV 24 weeks | Intervention Type: DRUG; Name: RBV; Assigned to Arm(s): LDV/SOF+RBV 12 weeks, LDV/SOF+RBV 24 weeks
D: Arm Label: BI 207127 low dose + SOC; Type: EXPERIMENTAL; Interventions: Drug: BI 207127 low dose + SOC | Arm Label: BI 207127 middle dose +SOC; Type: EXPERIMENTAL; Interventions: Drug: BI 207127 middle dose +SOC | Arm Label: BI 207127 high dose+SOC; Type: EXPERIMENTAL; Interventions: Drug: BI 207127 high dose+SOC | Arm Label: Placebo + SOC; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo + SOC | Intervention Type: DRUG; Name: BI 207127 middle dose +SOC; Assigned to Arm(s): BI 207127 middle dose +SOC | Intervention Type: DRUG; Name: BI 207127 high dose+SOC; Assigned to Arm(s): BI 207127 high dose+SOC | Intervention Type: DRUG; Name: Placebo + SOC; Assigned to Arm(s): Placebo + SOC | Intervention Type: DRUG; Name: BI 207127 low dose + SOC; Assigned to Arm(s): BI 207127 low dose + SOC

Answer: A